Program
GRPR-targeting Radioconjugate LY4257496
Its studies are mostly in Breast Neoplasms, led by Eli Lilly.
Furthest: phase 1, since Jul 30, 20251 company-led study, 1 open or runningNext primary completion: Apr 2030 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 11 open or running | phase 1since Jul 30, 2025 | Jul 30, 2025 | Apr 2030phase 1 · NCT07114601 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 30, 2025First study: phase 1 study in Breast NeoplasmsFirst studyNCT07114601 · 421 planned · United States, Canada, China and more
Ahead
- Apr 2030Primary completion: phase 1 study in Breast NeoplasmsNCT07114601
TargetBeta
GRPR →read by rule
“A radioconjugate consisting of a gastrin-releasing peptide receptor (GRPR)-targeting ligand, ”NCIt, by rule
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07114601Breast Neoplasms · United States, Canada, China and more | 1 | Recruiting | Apr 2030 | 421 |
How it is read
Names in the registry
- “LY4257496”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.